Literature DB >> 7936248

Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility-sensitized MRI.

P Hedera1, S Lai, E M Haacke, A J Lerner, A L Hopkins, J S Lewin, R P Friedland.   

Abstract

We studied activation of the human visual cortex (VC) using susceptibility-sensitized MRI at 1.5 Tesla. Three albinos and six healthy controls underwent a series of monocular and binocular photic flash stimulation. Monocular stimulation in albinos caused predominant contralateral activation with a small, well-delineated area in the anterior part of the VC in the ipsilateral hemisphere. This finding was consistent with a chiasmal crossing anomaly in albinism. All controls had symmetric patterns of activation during monocular stimulation. Functional MRI represents a promising method for evaluation of the visual pathways in humans.

Entities:  

Mesh:

Year:  1994        PMID: 7936248     DOI: 10.1212/wnl.44.10.1921

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Perceptual relevance of abnormal visual field representations: static visual field perimetry in human albinism.

Authors:  Michael B Hoffmann; Petra S Seufert; Linda C Schmidtborn
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

2.  Monocular visual activation patterns in albinism as revealed by functional magnetic resonance imaging.

Authors:  Bernd Schmitz; Barbara Käsmann-Kellner; Torsten Schäfer; Christoph M Krick; Georg Grön; Martin Backens; Wolfgang Reith
Journal:  Hum Brain Mapp       Date:  2004-09       Impact factor: 5.038

Review 3.  Rainer W. Guillery and the genetic analysis of brain development.

Authors:  Christopher A Walsh
Journal:  Eur J Neurosci       Date:  2018-09-17       Impact factor: 3.386

Review 4.  Using magnetic resonance imaging to assess visual deficits: a review.

Authors:  Holly D H Brown; Rachel L Woodall; Rebecca E Kitching; Heidi A Baseler; Antony B Morland
Journal:  Ophthalmic Physiol Opt       Date:  2016-05       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.